

Audit Review Table					
Blue Cross and Blue Shield of New Mexico, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company (Org ID: 1825, Sub ID: 9522, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)					
Measurement Year - 2024; Date & Timestamp - 6/3/2025 11:37:25 AM					
This submission is on the stage: Finalize Attestation					
Measure/Data Element	Benefit Offered	Rate	Status	Audit Designation	Comment
Effectiveness of Care					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)					
BMI percentile (Total)		71.53%	R	R	Reported
Counseling for Nutrition (Total)		58.88%	R	R	Reported
Counseling for Physical Activity (Total)		59.12%	R	R	Reported
Childhood Immunization Status (CIS)					
DTaP		72.99%	R	R	Reported
IPV		85.89%	R	R	Reported
MMR		86.86%	R	R	Reported
HiB		86.62%	R	R	Reported
Hepatitis B		85.64%	R	R	Reported
VZV		86.13%	R	R	Reported
Pneumococcal Conjugate		71.29%	R	R	Reported
Hepatitis A		87.83%	R	R	Reported
Rotavirus		70.07%	R	R	Reported
Influenza		34.55%	R	R	Reported
Combo 3		63.99%	R	R	Reported
Combo 7		54.74%	R	R	Reported
Combo 10		27.98%	R	R	Reported
Immunizations for Adolescents (IMA)					
Meningococcal		82.97%	R	R	Reported
Tdap		85.40%	R	R	Reported
HPV		38.20%	R	R	Reported
Combination 1		82.48%	R	R	Reported
Combination 2		37.23%	R	R	Reported
Lead Screening in Children (LSC)					
Lead Screening in Children		45.31%	R	R	Reported
Cervical Cancer Screening (CCS)					
Cervical Cancer Screening		47.93%	R	R	Reported
Chlamydia Screening in Women (CHL)					
(Total)		49.00%	R	R	Reported
Oral Evaluation, Dental Services (OED)	Y				
(0-2)		27.66%	R	R	Reported
(3-5)		56.89%	R	R	Reported
(6-14)		58.50%	R	R	Reported
(15-20)		39.90%	R	R	Reported
(Total)		49.46%	R	R	Reported
Topical Fluoride for Children (TFC)					
(1-2)		6.02%	R	R	Reported
(3-4)		6.61%	R	R	Reported
(Total)		6.31%	R	R	Reported
Appropriate Testing for Pharyngitis (CWP)	Y				
(Total)		79.18%	R	R	Reported
Pharmacotherapy Management of COPD Exacerbation (PCE)	Y				
Systemic Corticosteroid		55.72%	R	R	Reported
Bronchodilator		62.04%	R	R	Reported
Asthma Medication Ratio (AMR)	Y				
(Total)		85.06%	R	R	Reported
Controlling High Blood Pressure (CBP)					
Controlling High Blood Pressure		43.31%	R	R	Reported
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	Y				
Persistence of Beta-Blocker Treatment After a Heart Attack		45.45%	R	R	Reported
Statin Therapy for Patients With Cardiovascular Disease (SPC)	Y				
Received Statin Therapy (Total)		69.08%	R	R	Reported
Statin Adherence 80% (Total)		65.88%	R	R	Reported
Cardiac Rehabilitation (CRE)					

<i>Initiation (Total)</i>		3.89%	R	R	Reported
<i>Engagement1 (Total)</i>		4.17%	R	R	Reported
<i>Engagement2 (Total)</i>		4.72%	R	R	Reported
<i>Achievement (Total)</i>		1.94%	R	R	Reported
Glycemic Status Assessment for Patients With Diabetes (GSD)					
<i>Glycemic Status <8.0%</i>		45.26%	R	R	Reported
<i>Glycemic Status >9.0%</i>		47.45%	R	R	Reported
Blood Pressure Control for Patients With Diabetes (BPD)					
<i>Blood Pressure Control for Patients With Diabetes</i>		43.80%	R	R	Reported
Eye Exam for Patients With Diabetes (EED)					
<i>Eye Exam for Patients With Diabetes</i>		43.80%	R	R	Reported
Kidney Health Evaluation for Patients With Diabetes (KED)					
<i>(Total)</i>		33.65%	R	R	Reported
Statin Therapy for Patients With Diabetes (SPD)	Y				
<i>Received Statin Therapy</i>		52.66%	R	R	Reported
<i>Statin Adherence 80%</i>		63.59%	R	R	Reported
Diagnosed Mental Health Disorders (DMH)					
<i>(Total)</i>		29.01%	R	R	Reported
Antidepressant Medication Management (AMM)	Y				
<i>Effective Acute Phase Treatment</i>		60.65%	R	R	Reported
<i>Effective Continuation Phase Treatment</i>		42.09%	R	R	Reported
Follow-Up After Hospitalization for Mental Illness (FUH)	Y				
<i>30 days (Total)</i>		51.75%	R	R	Reported
<i>7 days (Total)</i>		30.78%	R	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	Y				
<i>30 days (Total)</i>		59.44%	R	R	Reported
<i>7 days (Total)</i>		47.33%	R	R	Reported
Diagnosed Substance Use Disorders (DSU)					
<i>Alcohol (Total)</i>		4.75%	R	R	Reported
<i>Opioid (Total)</i>		5.05%	R	R	Reported
<i>Other (Total)</i>		6.14%	R	R	Reported
<i>Any (Total)</i>		11.74%	R	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)	Y				
<i>30 days (Total)</i>		47.09%	R	R	Reported
<i>7 Days (Total)</i>		26.19%	R	R	Reported
Follow-Up After Emergency Department Visit for Substance Use (FUA)	Y				
<i>30 days (Total)</i>		35.72%	R	R	Reported
<i>7 days (Total)</i>		23.63%	R	R	Reported
Pharmacotherapy for Opioid Use Disorder (POD)	Y				
<i>(Total)</i>		17.26%	R	R	Reported
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	Y				
<i>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications</i>		82.30%	R	R	Reported
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)					
<i>Diabetes Monitoring for People With Diabetes and Schizophrenia</i>		65.92%	R	R	Reported
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)					
<i>Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia</i>		66.67%	NA	R	Reported
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	Y				
<i>Adherence to Antipsychotic Medications for Individuals With Schizophrenia</i>		57.77%	R	R	Reported
Appropriate Treatment for Upper Respiratory Infection (URI)	Y				
<i>(Total)</i>		81.38%	R	R	Reported
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	Y				
<i>(Total)</i>		55.69%	R	R	Reported
Use of Imaging Studies for Low Back Pain (LBP)					
<i>(Total)</i>		67.69%	R	R	Reported
Use of Opioids at High Dosage (HDO)	Y				

<i>Use of Opioids at High Dosage</i>		2.90%	R	R	Reported
Use of Opioids From Multiple Providers (UOP)	Y				
<i>Multiple Prescribers</i>		15.20%	R	R	Reported
<i>Multiple Pharmacies</i>		1.25%	R	R	Reported
<i>Multiple Prescribers and Multiple Pharmacies</i>		0.82%	R	R	Reported
Risk of Continued Opioid Use (COU)	Y				
<i>>=15 Days (Total)</i>		5.39%	R	R	Reported
<i>>=31 Days (Total)</i>		4.33%	R	R	Reported
Access/Availability of Care					
Adults' Access to Preventive/Ambulatory Health Services (AAP)					
<i>(Total)</i>		74.20%	R	R	Reported
Initiation and Engagement of Substance Use Disorder Treatment (IET)	Y				
<i>Initiation of SUD Treatment - Total (Total)</i>		50.01%	R	R	Reported
<i>Engagement of SUD Treatment - Total (Total)</i>		19.03%	R	R	Reported
Prenatal and Postpartum Care (PPC)					
<i>Timeliness of Prenatal Care</i>		81.02%	R	R	Reported
<i>Postpartum Care</i>		72.99%	R	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	Y				
<i>(Total)</i>		57.09%	R	R	Reported
Utilization and Risk Adjusted Utilization					
Well-Child Visits in the First 30 Months of Life (W30)					
<i>(First 15 Months)</i>		60.26%	R	R	Reported
<i>(15 Months-30 Months)</i>		67.83%	R	R	Reported
Child and Adolescent Well-Care Visits (WCV)					
<i>(Total)</i>		48.30%	R	R	Reported
Antibiotic Utilization for Respiratory Conditions (AXR)	Y				
<i>(Total)</i>		29.18%	R	R	Reported
Plan All-Cause Readmissions (PCR)			R	R	Reported
Health Plan Descriptive Information					
Enrollment by Product Line (ENP)			R	R	Reported
Language Diversity of Membership (LDM)			R	R	Reported
Race/Ethnicity Diversity of Membership (RDM)			R	R	Reported
Measures Reported Using Electronic Clinical Data Systems					
Childhood Immunization Status (CIS-E)					
<i>DTaP</i>		70.45%	R	R	Reported
<i>IPV</i>		84.46%	R	R	Reported
<i>MMR</i>		84.54%	R	R	Reported
<i>HiB</i>		83.81%	R	R	Reported
<i>Hepatitis B</i>		84.29%	R	R	Reported
<i>VZV</i>		84.04%	R	R	Reported
<i>Pneumococcal Conjugate</i>		69.23%	R	R	Reported
<i>Hepatitis A</i>		84.17%	R	R	Reported
<i>Rotavirus</i>		68.08%	R	R	Reported
<i>Influenza</i>		32.04%	R	R	Reported
<i>Combo 3</i>		61.11%	R	R	Reported
<i>Combo 7</i>		53.60%	R	R	Reported
<i>Combo 10</i>		24.11%	R	R	Reported
Immunizations for Adolescents (IMA-E)					
<i>Meningococcal</i>		83.54%	R	R	Reported
<i>Tdap</i>		84.82%	R	R	Reported
<i>HPV</i>		34.21%	R	R	Reported
<i>Combination 1</i>		82.77%	R	R	Reported
<i>Combination 2</i>		33.60%	R	R	Reported
Breast Cancer Screening (BCS-E)					
<i>Breast Cancer Screening</i>		47.31%	R	R	Reported
Cervical Cancer Screening (CCS-E)					
<i>Cervical Cancer Screening</i>		46.68%	R	R	Reported
Colorectal Cancer Screening (COL-E)					
<i>(Total)</i>		36.05%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)	Y				
<i>Initiation Phase</i>		49.56%	R	R	Reported
<i>Continuation and Maintenance Phase</i>		55.34%	R	R	Reported

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)	Y				
<i>Blood Glucose Testing (Total)</i>		61.67%	R	R	Reported
<i>Cholesterol Testing (Total)</i>		33.85%	R	R	Reported
<i>Blood Glucose and Cholesterol Testing (Total)</i>		33.21%	R	R	Reported
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)					
<i>Depression Screening (Total)</i>		0.61%	R	R	Reported
<i>Follow-Up on Positive Screen (Total)</i>		75.81%	R	R	Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)					
<i>Utilization of PHQ-9-Total (Total)</i>		1.62%	R	R	Reported
Depression Remission or Response for Adolescents and Adults (DRR-E)					
<i>Follow-Up PHQ-9 (Total)</i>		35.19%	R	R	Reported
<i>Depression Remission (Total)</i>		7.41%	R	R	Reported
<i>Depression Response (Total)</i>		12.96%	R	R	Reported
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)					
<i>Unhealthy Alcohol Use Screening (Total)</i>		0.00%	R	R	Reported
<i>Alcohol Counseling or Other Follow-Up Care (Total)</i>			NA	R	Reported
Adult Immunization Status (AIS-E)					
<i>Influenza (Total)</i>		16.59%	R	R	Reported
<i>Td/Tdap (Total)</i>		40.29%	R	R	Reported
<i>Zoster (Total)</i>		12.72%	R	R	Reported
<i>Pneumococcal (66+)</i>		51.82%	R	R	Reported
Prenatal Immunization Status (PRS-E)					
<i>Influenza</i>		29.23%	R	R	Reported
<i>Tdap</i>		62.89%	R	R	Reported
<i>Combination</i>		25.71%	R	R	Reported
Prenatal Depression Screening and Follow-Up (PND-E)					
<i>Depression Screening</i>		0.15%	R	R	Reported
<i>Follow-Up on Positive Screen</i>		100.00%	NA	R	Reported
Postpartum Depression Screening and Follow-Up (PDS-E)					
<i>Depression Screening</i>		0.13%	R	R	Reported
<i>Follow-Up on Positive Screen</i>		100.00%	NA	R	Reported
Social Need Screening and Intervention (SNS-E)					
<i>Food Screening (Total)</i>		0.00%	R	R	Reported
<i>Food Intervention (Total)</i>			NA	R	Reported
<i>Housing Screening (Total)</i>		0.00%	R	R	Reported
<i>Housing Intervention (Total)</i>			NA	R	Reported
<i>Transportation Screening (Total)</i>		0.00%	R	R	Reported
<i>Transportation Intervention (Total)</i>			NA	R	Reported